Connected With Latham

Episode 48 – M&A Views: Will UK-Bound M&A Need to Come to US Terms?

More US buyers — and more buyer-friendly deal terms — have entered the UK market, presenting an increasingly nuanced picture.

Episode 47 – Real Estate Realities in Europe: Expensive Money and the Power of Private Equity

After a long period of heightened dealmaking, activity may be down but this moment could now present good opportunities for cash buyers and opportunistic investors in multi-family, hospitality, logistics, and certain office markets.

Episode 46 – PE Views: PE Must Strike the Right Balance With Unions

PE acquirers should view unions as stakeholders and factor possible or actual engagement obligations with them into the deal process.

Episode 45 – Will Insurtech Reach New Heights in 2023?

Poised for a banner year, insurtech has drawn the attention of investors and regulators alike.

Episode 44 – PE Views: Private Equity Looks to Share-Based Schemes to Incentivise Non-Managerial Staff

Following recent press coverage, PE sponsors are exploring share-based schemes and other plans to incentivise non-managerial staff.

Episode 43 – Energy & Infrastructure: The Drivers and Opportunities of Asia’s Digital Infrastructure Boom

With half the world’s population and soon three billion mobile subscribers, the Asia Pacific region is set for long-term growth in digital infrastructure.

Episode 42 – PE Views: Has Rethinking Cannabis Sparked PE Interest?

Once shunned, the cannabis sector now offers attractive PE opportunities in many jurisdictions.

Episode 41 – PE Views: Why Do Music Deals Sound So Attractive to PE?

Music deals have struck a chord for PE investors, though notes of complexity remain.

Episode 40 – PE Views: Could PE Benefit From the Universal Adoption of “Super Senior” RCFs in Leveraged Financings?

Elevating the ranking of undrawn credit lines in PE financing could resolve a current short supply from banks.

Episode 39 – New FDA Commissioner Dr. Califf: What His Appointment Means for the Regulated Industry and What to Watch for in 2022

Dr. Robert Califf brings industry backing and a keen interest in using real world data to support FDA decision-making, emergency response, and safety monitoring.